Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2023

Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative, neovascular) form of the disease. Currently available therapies targeting vascular endothelial growth factor (VEGF)—including Roche / Genentech’s Avastin (bevacizumab), Roche / Genentech’s Lucentis (ranibizumab), Regeneron’s Eylea (aflibercept), and Novartis’s Beovu (brolucizumab)—have been shown to maintain and even improve visual acuity in wet AMD patients. Multiple new therapies have launched during our study period, including Roche / Genentech’s Susvimo and Vabysmo in November 2021 and February 2022, respectively, and Biogen / Samsung Bioepis’s Byooviz, the first biosimilar for ranibizumab, launched in July 2022. Using national, longitudinal, patient-level U.S. claims data, this report examines recent trends in the treatment of wet AMD among both newly diagnosed patients and patients filling a prescription for a key therapy in the first nine months of 2022. Because temporary or nonspecific HCPCS codes were used for claims of newly launched agents, we were unable to separate them out, but we comment on the use of nonspecific biologic codes where appropriate in our analysis.

QUESTIONS ANSWERED

• What patient shares do key brands garner by line of therapy in newly diagnosed wet AMD? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet AMD patients?
• How have biosimilar versions of Avastin (Amgen’s Mvasi and Pfizer’s Zirabev) been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of wet AMD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of wet AMD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Roche / Genentech, Regeneron, Novartis, Biogen, Samsung Bioepis

Key drugs: Avastin, Eylea, Lucentis, Beovu, Mvasi, Zirabev, Vabysmo,* Susvimo,* Byooviz*

*Patient-share data for these agents are not individually parsed.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.